Scientists at the ALS Therapy Development Institute are conducting research on this small molecule to determine whether or not it can be used as an effective treatment for ALS by addressing the dysfunctional UPR in motor neurons of PALS.
We are working to develop a formulation strategy for this small molecule so that it can be effectively screened using preclinical models of ALS.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!